Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 86Carcinoma, Renal Cell 29Lymphoma 26Kidney Neoplasms 26Leukemia 25Leukemia, Myeloid, Acute 24Lymphoma, Follicular 16Lymphoma, Non-Hodgkin 15Lymphoma, Mantle-Cell 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Breast Neoplasms 12Neoplasm Metastasis 11Lymphoma, Large B-Cell, Diffuse 10Lymphoma, B-Cell, Marginal Zone 10Skin Neoplasms 9Myelodysplastic Syndromes 9Lymphoma, Large-Cell, Immunoblastic 9Hodgkin Disease 9Burkitt Lymphoma 9Neuroblastoma 8Congenital Abnormalities 8Recurrence 7Ovarian Neoplasms 7Multiple Myeloma 7Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Leukemia, Myelomonocytic, Chronic 6Gliosarcoma 6Glioblastoma 6

Interventions

senaparib 7pembrolizumab 7Irinotecan 6Paclitaxel 5Docetaxel 5Cisplatin 5Capecitabine 5Nivolumab 4Fluorouracil 4Bevacizumab 4Rifampin 3Midazolam 3Leucovorin 3Itraconazole 3Injections 3pertuzumab 2ontuxizumab 2navoximod 2atezolizumab 2Gemcitabine 2vofatamab 1tremelimumab 1trastuzumab duocarmazine 1talazoparib 1sotorasib 1sintilimab 1saracatinib 1rucaparib 1ridaforolimus 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumor × aldesleukin × Clear all
NCT04862767 2024-01-31

TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor

Autotelicbio

Phase 1 Completed
9 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡